Home » Topics » BioWorld Science, Conferences

BioWorld Science, Conferences
RSS

Roche and Genentech prepare prodrugs of fibrinogen antagonist

Sep. 6, 1996

Thalidomide derivatives as leads for septic shock therapy

Sep. 6, 1996

Arginine analogues for shock

Sep. 6, 1996

CGS-28106 for hypertension and congestive heart failure

Sep. 6, 1996

Zambon selects a dopaminergic compound for evaluation in cardiovascular/renal disorders

Sep. 6, 1996

Orally active dual NK1/NK2 antagonist from Merck & Co.

Sep. 6, 1996

New adenosine A3 receptor antagonist reported at ACS

Sep. 6, 1996

Potential new treatment for Alzheimer's disease disclosed by SIBIA Neurosciences

Sep. 6, 1996

Reversible MAO inhibitors from Hoechst Marion Roussel

Sep. 6, 1996

A new CETP inhibitor from Schering-Plough

Sep. 6, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...